Press Release | Mon Jul 1, 2013 5:05pm EDT

FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients

* Reuters is not responsible for the content in this press release.